TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES
Dead / Abandoned — Abandoned — failure to respond (as of 16 Feb 2024)
What this means for you
This application is over — abandoned 05 Feb 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97769288
- Mark type
- Stylized text
- Filed
- 26 Jan 2023
- Abandoned
- 05 Feb 2024
- Attorney of record
- Melanie Howard
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations; viruses; viruses for the treatment of disease; viruses for the treatment of cancer; viruses for inducing immune response; pharmaceuticals; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response; vaccines; immunotherapy products; gene therapy products; Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders
- Class 042 — Scientific and technological services: Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaid
Owner
- Replimune Limited, Abingdon, Oxfordshire, GB
Prosecution history
- 16 Feb 2024 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 16 Feb 2024 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 02 Nov 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 02 Nov 2023 — NON-FINAL ACTION E-MAILED
- 02 Nov 2023 — NON-FINAL ACTION WRITTEN
- 24 Oct 2023 — ASSIGNED TO EXAMINER
- 15 Feb 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 30 Jan 2023 — NEW APPLICATION ENTERED